We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Reply.
- Authors
Poon, L. C.; Martinez‐Portilla, R.; Martinez-Portilla, R
- Abstract
It is crucial that every effort is made to identify patients who may still develop pre-eclampsia despite aspirin prophylaxis because they should be provided with appropriate advice to be vigilant of pre-eclampsia symptoms and seek medical attention, when necessary. Through the ASPRE (Combined Multimarker Screening and Randomized Patient Treatment with Aspirin for Evidence-Based Pre-eclampsia Prevention) trial, we have demonstrated that aspirin prophylaxis given to high-risk women, identified by first-trimester combined screening based on maternal factors, mean arterial pressure (MAP), uterine artery Doppler, serum pregnancy-associated plasma protein-A and serum placental growth factor (PlGF), achieved a 62% reduction in the incidence of preterm pre-eclampsia1. In addition, aspirin treatment partially reversed a wide range of metabolic changes over gestation, lending further support to our hypothesis that the benefit of aspirin treatment in preventing pre-eclampsia is mediated through decelerating the metabolic clock of gestation6.
- Subjects
ECLAMPSIA; HIGH-risk pregnancy; PLACENTAL growth factor; PREGNANCY complications
- Publication
Ultrasound in Obstetrics & Gynecology, 2021, Vol 58, Issue 4, p643
- ISSN
0960-7692
- Publication type
letter
- DOI
10.1002/uog.24761